Board - Immedica

Thomas Eklund

Chairman of the board

Thomas Eklund has an MBA from Stockholm School of Economics and works as an independent advisor, chairman and investor in Life Science companies. Advisor to Impilo AB and Patricia Industries AB ( Investor AB), Chairman in Sedana Medical AB and Mabtech AB and board member of Biotage AB, Boule Diagnostics AB and Swedencare AB.

Thomas has an extensive background from investments and development of Life Science companies as Head of Investor Growth Capital Europé, AAC Capital, Chairman of Swedish Orphan International, Calliditas, GHP Speciality Care and Biotage.

Lisa Bright

Board member

Lisa Bright brings 30 years experience in the pharmaceutical industry both as a senior Executive and a Board Member. Currently she also serves as a non Executive Director for Ascendis Pharma (Listed on NASDAQ), DECHRA pharma (listed on FTSE) and Resolution Therapeutics Ltd.

Lisa served as President International and Chief Commercial and Corporate Affairs Officer for Intercept Pharmaceuticals, Inc where she oversaw the development of the global launch of an orphan medicine in the US and Europe, including building the commercial organization in the US and across Europe and Canada and globally through partnerships. Lisa held senior leadership positions at Gilead Sciences Ltd., including Vice President, Head Government Affairs, Europe, Asia, Middle East and Australasia, Vice President and Head of HCV Launch Planning, Vice President and Head of Northern Europe and General Manager, UK and Ireland. Ms. Bright received her B.Sc. in Pharmacology from University College London, United Kingdom.

Magnus Edlund

Board member

Magnus is Impilo’s responsible partner for Immedica and has 12 years of active ownership and governance experience within private equity and healthcare. Prior to joining Impilo in 2017, Magnus worked for Altor Equity Partners between 2009 and 2017 and for the Boston Consulting Group between 2004 and 2009. Magnus currently also serves on the Board of Directors for NutraQ and has previously served on the Boards of Orchid Orthopedics and Rossignol.

Fredrik Holmström

Board observer

Fredrik is an Investment Manager with Impilo and has been working actively with Immedica since its foundation in 2018. Prior to joining Impilo in 2017, Fredrik worked for XIO Group between 2015 and 2017 and for Bank of America Merrill Lynch between 2013 and 2015.

Stefan Larsson

Board member

Stefan has an extensive background in the health care industry where he during his years (1996-2020) at BCG founded and lead their Global Payer & Provider-, Global Health Systems sector and as a BCG fellow at the Bruce Henderson institute lead the work in Value based health care. His experience includes a numerous strategy assignments across the value chain eg. Global Sales Force effectiveness, Manufacturing, In licensing strategy; Clincal development, Regulatory and Commercial compliance. Hels also has a broad range of Industry Strategy assignments for Biotech and MedTech companies across Europe as well as Health care market strategy for global leaders in telecom, steel and software.

Stefan holds an M.D. from the Karolinska Institute, Stockholm (KI) and has PhD-Studies in Pediatric Nephrology at KI and Harvard Medical School. He is a cofounder and board-member of ICHOM – International Consortium for Health Outcomes Measurement, Not-for-profit developing global standards for outcomes that matter for patients and a Fellow of the World Economic Forum Health and Healthcare team since 2020.

Kerstin Valinder

Board member

Kerstin Valinder Strinnholm brings 30 years of experience from the international pharmaceutical industry.

Kerstin was EVP Business development and Corporate strategy in Nycomed Group (now Takeda), joining from AstraZeneca where she had leading positions in marketing and business development.

Current assignments include membership of the boards of Camurus AB, Promore Pharma AB, Moberg Pharma AB (publ) and Bioservo Technologies AB (publ).

Peder Walberg

Board member

Peders background includes being the founder and CEO of Rare Thyroid Therapeutics and Medical Need Europe and co-founder of Wilson Therapeutics. Peder has also served as EVP Business Development and Strategy at Swedish Orphan and Sobi and Nordic Head of New Products and BD&L at Novartis. He has previously been a director of the board of Wilson Therapeutics and OxThera and is currently on the boards of Immedica and PledPharma. Peder is a registered physician with an MD from Uppsala University, a BSc in International Economics and Business Administration from the same university and has a background as a management consultant with the Boston Consulting Group.